|
20 Jan 2021 |
Doptelet® (avatrombopag) approved in the EU for treatment of ITP
|
|
20 Jan 2021 |
Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer
|
|
19 Jan 2021 |
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
|
|
19 Jan 2021 |
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
|
|
19 Jan 2021 |
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
|
|
18 Jan 2021 |
Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy
|
|
18 Jan 2021 |
Ixaka (formerly Rexgenero) launches as an integrated cell and gene therapy company
|
|
18 Jan 2021 |
Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
|
|
18 Jan 2021 |
Positive Phase 1 results in high-dose setanaxib trial
|
|
18 Jan 2021 |
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium
|
|
18 Jan 2021 |
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
|
|
16 Jan 2021 |
Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
|
|
16 Jan 2021 |
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
|
|
16 Jan 2021 |
Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer
|
|
16 Jan 2021 |
Zanidatamab Data Highlight Durable Antitumor Activity in HER2 Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
|
|
16 Jan 2021 |
ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
|
|
15 Jan 2021 |
Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D)
|
|
15 Jan 2021 |
Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis
|
|
15 Jan 2021 |
Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
|
|
15 Jan 2021 |
Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
|
